HC Wainwright Reiterates “Buy” Rating for BioLife Solutions (NASDAQ:BLFS)

HC Wainwright restated their buy rating on shares of BioLife Solutions (NASDAQ:BLFS) in a report issued on Tuesday morning,Benzinga reports. They currently have a $30.00 price target on the medical equipment provider’s stock. HC Wainwright also issued estimates for BioLife Solutions’ Q2 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.00 EPS and FY2026 earnings at $0.03 EPS.

Separately, StockNews.com cut BioLife Solutions from a “hold” rating to a “sell” rating in a report on Thursday, April 24th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, BioLife Solutions currently has an average rating of “Moderate Buy” and an average price target of $31.17.

BioLife Solutions Stock Performance

NASDAQ:BLFS opened at $21.99 on Tuesday. The stock has a market cap of $1.04 billion, a P/E ratio of -20.75 and a beta of 2.01. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The stock’s 50-day moving average is $23.58 and its 200-day moving average is $25.29. BioLife Solutions has a 1-year low of $18.70 and a 1-year high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. The company had revenue of $23.94 million for the quarter, compared to analysts’ expectations of $22.22 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. Equities research analysts anticipate that BioLife Solutions will post -0.3 earnings per share for the current year.

Insider Transactions at BioLife Solutions

In other news, CFO Troy Wichterman sold 25,687 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $582,067.42. Following the transaction, the chief financial officer now directly owns 189,242 shares of the company’s stock, valued at $4,288,223.72. This represents a 11.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Sarah Aebersold sold 5,771 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total value of $130,770.86. Following the transaction, the insider now directly owns 80,094 shares in the company, valued at $1,814,930.04. The trade was a 6.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,696 shares of company stock valued at $1,665,094 over the last ninety days. 2.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On BioLife Solutions

Large investors have recently bought and sold shares of the stock. Proficio Capital Partners LLC bought a new position in BioLife Solutions during the 4th quarter valued at $638,000. Alliancebernstein L.P. lifted its stake in BioLife Solutions by 11.9% during the 4th quarter. Alliancebernstein L.P. now owns 37,351 shares of the medical equipment provider’s stock valued at $970,000 after acquiring an additional 3,967 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in BioLife Solutions by 18.6% during the 4th quarter. Envestnet Asset Management Inc. now owns 198,695 shares of the medical equipment provider’s stock valued at $5,158,000 after acquiring an additional 31,167 shares in the last quarter. Victory Capital Management Inc. lifted its stake in BioLife Solutions by 422.2% during the 4th quarter. Victory Capital Management Inc. now owns 218,962 shares of the medical equipment provider’s stock valued at $5,684,000 after acquiring an additional 177,028 shares in the last quarter. Finally, D.A. Davidson & CO. lifted its stake in BioLife Solutions by 1.3% during the 4th quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock valued at $1,069,000 after acquiring an additional 519 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.